Clinical Trial Update: SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1. [Phase 4]

View source ↗

Summary

This trial update reports on the Phase 4 SYREN study evaluating PEGASYS (peginterferon alfa-2a, 40 kDa) plus Copegus (ribavirin) in non-responder patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED